Maya Abdallah's research while affiliated with Boston University and other places

... Myeloid neoplasms can have a rapid onset requiring initiation of treatment within a few days to weeks. 52 During treatment and especially within the first few months following diagnosis, older patients often experience serious toxicities requiring hospitalization. 53 Impairments in geriatric assessment domains further complicate the course of treatment. ...

... Multimorbidity, commonly defined as the coexistence of multiple chronic diseases and/or conditions within one individual, is prevalent among older populations (Salive, 2013). Multimorbidity has been associated with functional limitations (Kadambi et al., 2020), poor quality of life (Kanesarajah et al., 2018), and mortality (Nunes et al., 2016). With a rapidly aging global population, multimorbidity poses a great economic burden on both individuals and health care systems (Larkin et al., 2021;Soley-Bori et al., 2021). ...

... The standard induction chemotherapy regimen consists of a combination of cytarabine and anthracycline (especially daunorubicin) administered for 7 and 3 d, respectively. The aim of the '7 + 3' regime is to achieve a complete remission (CR); however, the results are not always satisfactory, as CR is achieved in 40%-60% of people older than 60 years and in 60%-80% of younger adults, while a post-remission therapy may be required to ensure a continuous remission [4][5][6][7]. Cytarabine and daunorubicin combined at a molar ratio 5:1, encapsulated in a liposome with a composition suitable for the uptake preferentially by leukemia cells, called CPX-351, is an alternative providing better results [8][9][10]. Radiotherapy is usually applied as a supplementary therapy to suppress AML that has spread outside of the bone marrow and blood and can be used in a preparation phase for HSCT [11,12]. ...

... Costs of healthcare can be a significant barrier for many patients, and CR is no exception. In one study the presence of any co-pays or unmet deductibles in patients referred to CR was associated with 6 J o u r n a l P r e -p r o o f fewer sessions of CR completed, with a dose-response relationship between increasing levels of costshare and fewer sessions completed [64]. While it is reasonable to assume that the elimination of co-pays and deductibles would result in a higher rate of participation in CR, to the best of our knowledge, such a study has not been performed. ...

... Although the EORTC QLQ-C30 has been validated in patients with cancer and utilized in a third of prior AML studies, it is neither disease nor treatment-specific [5,6]. In addition, pre-defined deterioration thresholds of ≥10, 7, and 5 points in EORTC QLQ-C30, EQ-5D-5L VAS, and PROMIS Fatigue, respectively, may not always capture clinically meaningful changes in function. ...

... 36 37 This is because palliative care among hospitalized patients in the USA is provided selectively, being used preferentially in patients considered by clinicians as very likely to die or when death is seen as imminent, and thus palliative care is much more common among patients who die in the hospital. [36][37][38] Patients receiving palliative care may have life support interventions withheld or withdrawn in accordance with patients' goals of care. Thus, although we could not determine the timing of palliative care in relation to withholding or withdrawing of life support from our data set, inclusion of palliative care in our models, as employed in prior epidemiological studies using administrative data, 37 can address in part the confounding effect of these practices on the effect size of other modeled covariates and could improve the accuracy of the observed estimates. ...